Holen Sie sich die Stockscreener-App
38.92
1.35%
-0.69
Schlusskurs vom Vortag:
$39.61
Offen:
$39.62
24-Stunden-Volumen:
844.97K
Relative Volume:
0.90
Marktkapitalisierung:
$2.09B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-119.95M
KGV:
-19.34
EPS:
-2.0123
Netto-Cashflow:
$-95.28M
1W Leistung:
+12.94%
1M Leistung:
+11.52%
6M Leistung:
+190.97%
1J Leistung:
+404.87%
1-Tages-Spanne:
$38.72
$40.51
1-Wochen-Bereich:
$34.84
$40.65
52-Wochen-Spanne:
$6.42
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
Firmenname
Tyra Biosciences Inc
Sektor
Branche
Telefon
(619) 728-4760
Adresse
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
38.89 | 2.13B | 0 | -119.95M | -95.28M | -2.0123 |
VRTX
Vertex Pharmaceuticals Inc
|
433.58 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.40 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.05 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.89 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.74 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-02-10 | Eingeleitet | William Blair | Outperform |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-05-21 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-07 | Eingeleitet | UBS | Buy |
| 2024-10-18 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-08-15 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-30 | Eingeleitet | Wedbush | Outperform |
| 2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
| 2022-06-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-03-08 | Hochstufung | Jefferies | Hold → Buy |
| 2021-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2021-10-11 | Eingeleitet | BofA Securities | Buy |
| 2021-10-11 | Eingeleitet | Cowen | Outperform |
| 2021-10-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Tyra Biosciences Inc Aktie (TYRA) Neueste Nachrichten
Canaccord Genuity Group Begins Coverage on Tyra Biosciences (NASDAQ:TYRA) - MarketBeat
Canaccord Genuity Initiates Tyra Bioscience at Buy With $50 Price Target - marketscreener.com
Growth Stocks To Watch Now – April 3rd - Defense World
A Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial Progress - Yahoo Finance
Promising Growth Stocks To Watch Today – April 2nd - Defense World
Tyra Biosciences announces $126 million stock sale in block transaction - Investing.com
Tyra Bioscience Strengthens Financial Leadership with New Officer - TipRanks
Tyra Biosciences (TYRA) VP details multi-year stock option grants - Stock Titan
Tyra Biosciences names Julia Rueb principal accounting officer, succeeding Alan Fuhrman - TradingView
Tyra Biosciences (NASDAQ: TYRA) taps Julia Rueb as principal accounting officer - Stock Titan
Tyra Biosciences stock hits all-time high at 39.21 USD By Investing.com - Investing.com South Africa
Barclays Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $59 - 富途牛牛
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Growth Stocks Worth Watching – March 31st - Defense World
Precision Trading with Tyra Biosciences Inc. (TYRA) Risk Zones - news.stocktradersdaily.com
Tyra Biosciences (NASDAQ:TYRA) Reaches New 1-Year HighWhat's Next? - MarketBeat
Tyra Biosciences stock hits all-time high at 39.21 USD - investing.com
Tyra Biosciences (NASDAQ:TYRA) Trading 9.8% HigherShould You Buy? - MarketBeat
Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans - 富途牛牛
Wedbush maintains Tyra Biosciences (TYRA) outperform recommendation - MSN
Tyra Biosciences (NASDAQ:TYRA) Director Sells $528,486.15 in Stock - MarketBeat
Tyra Biosciences director Kaplan sells shares worth $528k By Investing.com - au.investing.com
Tyra Biosciences director Kaplan sells shares worth $528k - Investing.com
Tyra Biosciences (NASDAQ: TYRA) director exercises 67,467 options, sells and returns shares - Stock Titan
Insider plans sale of 53,172 TYRA shares via option exercise (TYRA) - Stock Titan
Piper Sandler reiterates Tyra Biosciences stock rating on oral therapy potential - Investing.com Canada
[144] Tyra Biosciences, Inc. SEC Filing - Stock Titan
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ - openPR.com
Non Muscle Invasive Bladder Cancer Clinical Trial Pipeline - openPR.com
Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma - Barchart.com
Non Muscle Invasive Bladder Cancer Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com
Highs Report: Is Tyra Biosciences Inc forming a breakout patternChart Signals & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Non Muscle Invasive Bladder Cancer Pipeline Expands As 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds Delveinsight CG Oncology, Janssen, Tyra Biosciences, Urogen Pharma - Mena FN
Dabo gratinib designation honors key Tyra Biosciences executives - tradersunion.com
Tyra Biosciences (NASDAQ:TYRA) Trading Down 4.5%Should You Sell? - MarketBeat
Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Performance - Sahm
Best Growth Stocks To Follow Today – March 20th - Defense World
Piper Sandler Increases Tyra Biosciences (NASDAQ:TYRA) Price Target to $56.00 - Defense World
Technical Reactions to TYRA Trends in Macro Strategies - news.stocktradersdaily.com
Boone Capital Backs Tyra Biosciences As FGFR3 Trials Shape Outlook - Sahm
Cantor Fitzgerald initiates coverage of Tyra Biosciences (TYRA) with overweight recommendation - MSN
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position - AOL.com
Boone Capital Invests in Tyra Biosciences: $10.48M Stake AcquiredNews and Statistics - IndexBox
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 - The Motley Fool
Piper Sandler Issues Positive Forecast for Tyra Biosciences (NASDAQ:TYRA) Stock Price - MarketBeat
Piper Sandler Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $56 - 富途牛牛
Tyra Biosciences (TYRA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Forecast Cut: Can Tyra Biosciences Inc continue delivering strong returnsIPO Watch & Smart Swing Trading Techniques - baoquankhu1.vn
Hedge Fund Bets: Is Tyra Biosciences Inc a strong candidate for buy and holdQuarterly Portfolio Report & Smart Allocation Stock Tips - baoquankhu1.vn
Tyra Biosciences (TYRA) CFO adds 1,376 shares via employee stock plan - Stock Titan
Tyra Biosciences (TYRA) CEO adds 1,463 ESPP shares, holdings reach 1.36M - Stock Titan
Finanzdaten der Tyra Biosciences Inc-Aktie (TYRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tyra Biosciences Inc-Aktie (TYRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KAPLAN GILLA | Director |
Mar 25 '26 |
Sale |
36.97 |
14,295 |
528,506 |
28,231 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):